United States· US:50881-023_b6b9ef2d-53cd-47c7-9ee5-c0610635d35b

NIKTIMVO

A axatilimab product containing axatilimab, registered in United States by Incyte Corporation.

ATC L04AG19

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedNIKTIMVOATCL04AG19REGISTER NO.US:50881-023_b6b9ef2d…PACKS LISTED1CHECKEDSeptember 20, 2026

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
AXATILIMAB
Manufacturer
Incyte Corporation
Country
United States (US)
ATC code
L04AG19
ATC class
Axatilimab
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 20, 2026

Packs & prices · 1

  • ndc11
    50881-023-11

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fde1e08d-929f-41ae-9421-95dc3c1fba30
GET /v1/drugs/fde1e08d-929f-41ae-9421-95dc3c1fba30?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "INTRAVENOUS",
  "source": "ndc",
  "strength": "22",
  "substance": "AXATILIMAB",
  "productndc": "50881-023",
  "dosage_form": "INJECTION",
  "dea_schedule": null,
  "strength_unit": "mg/.44mL",
  "application_number": "BLA761411",
  "marketing_category": "BLA"
}

See everything about axatilimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.